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Aberrant cholesterol homeostasis and biosynthesis has been observed in different tumour types. This paper
investigates the role of the post-squalenic enzyme of cholesterol biosynthesis, oxidosqualene cyclase (OSC),
in regulating tumour angiogenesis and metastasis dissemination in mouse models of cancer. We showed
that Ro 48-8071, a selective inhibitor of OSC, reduced vascular density and increased pericyte coverage, with
a consequent inhibition of tumour growth in a spontaneousmousemodel of pancreatic tumour (RIP-Tag2)
and two metastatic mouse models of human colon carcinoma (HCT116) and pancreatic adenocarcinoma
(HPAF-II). Remarkably, the inhibition of OSC hampered metastasis formation in HCT116 and HPAF-II
models. Ro 48-8071 induced tumour vessel normalization and enhanced the anti-tumoral and anti-metastatic
effects of 5-fluorouracil (5-FU) in HCT116 mice. Ro 48-8071 exerted a strong anti-angiogenic activity by
impairing endothelial cell adhesion and migration, and by blocking vessel formation in angiogenesis
assays. OSC inhibition specifically interfered with the PI3K pathway. According to in vitro results, Ro
48-8071 specifically inhibited Akt phosphorylation in both cancer cells and tumour vasculature in all
treated models. Thus, our results unveil a crucial role of OSC in the regulation of cancer progression
and tumour angiogenesis, and indicate Ro 48-8071 as a potential novel anti-angiogenic and anti-metastatic
drug.
T
he critical role of angiogenesis in regulating tumour growth and metastasis formation has long been
appreciated1. Though several anti-angiogenic drugs, such as inhibitors of the vascular endothelial growth
factor (VEGF) pathway, have been approved in clinical practice for the treatment of different tumor types,
the results of clinical trials have not replicated the promising effects observed in preclinical models in terms of
metastasis formation and progression2,3. Hence, there is a pressing need to identify new angiogenic targets and
therapeutic strategies to improve the current anti-angiogenic treatments in cancer patients. Recent findings have
highlighted a crucial role played by the metabolism in regulating angiogenesis in several diseases, and there is a
growing interest in elucidating the underlying mechanisms in order to find new ‘‘metabolic’’ targets and drugs to
inhibit angiogenesis in cancers4,5.
In the framework of the role of metabolism and tumours, it is widely known that aberrant regulation of
cholesterol homeostasis has been reported to occur in multiple types of cancer6,7. Several inhibitors of the
cholesterol pathway have been described tomodulate both tumour growth and angiogenesis. For instance, statins,
HMGCoA reductase (HMGR) inhibitors, displayed a biphasic effect both in promoting and inhibiting angiogen-
esis and tumour growth8. Side effects can be partly explained by the fact that the sterol biosynthesis pathway
supplies the prenyl intermediates used for post-translational modifications of proteins. In turn, prenylation
regulates intracellular localisation and the activity of several signalling transducers, such as small GTPases that
are prominently involved in regulating cancer progression7. Terbinafine and itraconazole are two antifungal
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drugs that impair the post-squalenic steps of cholesterol synthesis.
The anti-angiogenic properties of these drugs have been previuosly
described, as they inhibit proliferation and differentiation of human
endothelial cells (ECs)9,10. More recently, itraconazole has been
shown to impair tumor growth and angiogenesis in primary xeno-
graft models of human non-small cell lung cancer11 and in a mouse
model of medulloblastoma12 and terbinafine has been shown to
inhibit tumor growth and angiogenesis13. Terbinafine is an effective
inhibitor of squalene monooxygenase14, while itraconazole blocks
sterol biosynthesis by inhibiting 14-demethylase15 (Figure 1A). Both
compounds inhibit the sterol biosynthetic pathway after the forma-
tion of prenyl intermediates, suggesting that the anti-angiogenic effect
should be based on a mechanism other than inhibition of the meva-
lonate pathway and of isoprenoid biosynthesis, which has been
suggested as a cause of the anti-angiogenic and anti-tumoral activity
observed in statins7,8. Though these findings suggest an important
role of post-squalenic enzymes and of their inhibitors in tumor
growth and angiogenesis, to date none of the described compounds
have been described to efficiently impair tumor angiogenesis
in parallel with a significant inhibition of metastasis formation.
Moreover, the mechanisms that regulate the relationship between
tumour angiogenesis and cholesterol biosynthesis are widely unknown.
In the present work, we studied the role of an important post-
squalenic enzyme, 2,3-oxidosqualene lanosterol cyclase (OSC), that
cyclizes the 2,3-oxidosqualene leading the formation of lanosterol, a
key intermediate in the biosynthesis of cholesterol (Figure 1A). We
assessed whether blocking sterol synthesis with the selective OSC
inhibitor Ro 48-8071, shown to significantly decrease sterol biosyn-
thesis and cell cholesterol contents in both cell culture and animals16,
could induce anti-angiogenic and anti-metastatic effects in preclini-
cal cancer models. Similarly to terbinafine and itraconazole, Ro 48-
8071 is able to significantly decrease the sterol biosynthesis and cell
cholesterol contents, without affecting the formation of the prenyl
intermediates17.
This paper describes the activity of Ro 48-8071 as a potent inhib-
itor of tumor-associated angiogenesis, cancer growth and meta-
stasis dissemination to distal organs in a spontaneous mouse
model of neuroendocrine pancreatic tumor (RIP-Tag2), in human
colon carcinoma (HCT116) and in pancreatic ductal adenocarci-
noma (HPAF-II) xenograft mouse models. We show improved
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Figure 1 | Ro 48-8071 inhibits primary tumour growth in a spontaneous mouse model of pancreatic cancer and blocks metastasis formation in both
HCT116 andHPAF-II models. (A) Representation of cholesterol biosynthesis. This process includes a pre-squalenic phase and a post-squalenic step and
offers a number of potential therapeutic targets, which can affect the mevalonate pathway (statins) or block, downstream of the formation of prenyl
intermediates, the synthesis of lanosterol and cholesterol (e.g. OSC and C14-demethylase, inhibited by Ro 48-8071 and itraconazole, respectively).
(B) 10 mg/kg of Ro 48-8071 or vehicle as control were orally administrated to established tumour-bearing mice (n5 10/group). Total tumor burden was
reduced by 40% in RIP-Tag2 mice treated with Ro 48-8071 versus controls (n 5 10; **P , 0.001). (C,D) Tumor growth curve of HCT116
and HPAF-II xenografts. Mean 6SEM tumor volumes are reported for each treatment of HCT116 (C) and HPAF-II (D) xenograft mouse models
(n 5 10; *P , 0.05). (E–G) Metastatic dissemination per animal. Treatment with Ro 48-8071 reduced the number (E) and the incidence (F) of lung
metastasis in HCT116 mice by 81% and 53%, respectively, compared with controls, and decreased the incidence (G) and number (H) of liver metastasis
by 75% and 60% respectively in HPAF-II mice (*P , 0.05; **P , 0.001).
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anti-tumoral efficacy by combining Ro 48-8071 with standard cy-
totoxic chemotherapy. Inhibition of OSC specifically blocked the
PI3K/Akt signalling pathway in both tumour vasculature and cancer
cells. These studies are the first assessment of the efficacy of Ro
48-8071 as an anti-angiogenic and anti-metastatic agent in murine
cancer models.
Results
The inhibition of OSC impairs tumor growth and blocks
metastatic dissemination in RIP-Tag2, HCT116 and HPAF-II
mouse models. The pharmacological properties of Ro 48-8071 as a
selective inhibitor of the post-squalenic enzyme OSC have been well
characterised, and Ro 48-8071 is known to block human liver OSC
and cholesterol synthesis at nanomolar range16. First, we treated with
Ro 48-8071 tumor-bearing RIP-Tag2 mice, a transgenic mouse
model of spontaneous neuroendocrine pancreatic cancer. This is a
well-characterised mouse model and suitable platform that is widely
used to perform pre-clinical trials to assess drug ability to impair
angiogenesis and inhibit tumor growth18,19. Based on several in
vivo evidences16,20 and our preliminary results, we set up the most
effective and less toxic concentration of Ro 48-8071 (data not
shown). We found that RIP-Tag2 orally receiving 10 mg/kg/daily
of Ro 48-8071 did not show a significant decrease in total body
weight during the treatment, and healthy organs, such as kidney,
lung and liver, were not affected (Supplementary Figures S1A–
S1D). Therefore, we performed a regression trial of 4 weeks in
RIP-Tag2 mice, from the 12th until the 16th week of age. This
treatment is aimed at targeting advanced, well-established cancers
and at testing the ability of a drug to shrink large tumours.
Interestingly, while vehicle-treated RIP-Tag2 mice died at 14 weeks
of age, all the Ro 48-8071 treated mice were still alive until the end of
the regression trial (16 weeks) and displayed an inhibition of tumour
growth by 40%, compared with untreated mice (Figure 1B). Next,
we assessed whether OSC inhibition was able to block cancer pro-
gression in human cancer cells and, to this end, we employed two
different xenograft mousemodels of colon carcinoma (HCT116) and
pancreatic ductal adenocarcinoma (HPAF-II). Of note, as observed
in RIP-Tag2 mice, both HCT116 and HPAF-II models harbouring
established tumors and treated with Ro 48-8071 for two weeks,
showed a significant tumor volume reduction by 46% and 47%,
respectively, compared with vehicle-treated controls (Figures 1C
and D). Remarkably, Ro 48-8071 strongly reduced metastasis dis-
semination to distal organs. Ro 48-8071 decresed the number (81%)
and the incidence (53%) of lung metastasis in HCT116 xenograft
(Figures 1E and F), and the incidence (75%) and number (60%)
of liver metastasis in HPAF-II mice, compared with controls.
(Figures 1G and 1H).
Ro 48-8071 strongly impairs tumour angiogenesis and normalizes
vasculature in RIP-Tag2, HCT116 and HPAF-II mouse models.
OSC inhibition efficiently reduced vessel area in RIP-Tag2 mice by
49% (Figure 2A), and in both HCT116 and HPAF-II xenografts by
67% and 56%, respectively (Figure 2B). Interestingly, we observed a
strong increase in pericyte coverage in tumor vessels of treated mice
(by 44% in RIP-Tag2, by 33% in HCT116 and by 31% in HPAF-II),
compared with controls (Figures 2C–G). Both results indicated that
OSC inhibition in cancers strongly impairs angiogenesis and induces
tumor blood vessel normalization, which, in turn, could contribute to
the reduction of metastasis formation21,22. Remarkably, Ro 48-8071
delivery did not affect the normal vasculature of either exocrine
pancreas (Supplementary Figures S2A and S2B) or normal islets
(data not shown) in late-stage tumor bearing RIP-Tag2 mice,
indicating that OSC inhibition results in a selective impairment
of cancer angiogenesis. Notably, by means of Pimonidazole
immunostaining we checked the hypoxic levels of RIP-Tag2
transgenic mice and of HCT116 and HPAF-II xenografts treated
with Ro 48-8071 in comparison with the corresponding untreated
mice. Interestingly, we found that Ro 48-8071 significantly reduced
hypoxia across all treatment groups (Supplementary Figures S3A–
S3D). This result further confirms that Ro 48-8071, by inducing the
normalization of tumor blood vessels significantly improves the total
tissue oxygenation.
By improving tumor tissue perfusion, Ro 48-8071 enhances the
anti-tumoral effect of 5- Fluorouracil in human colon carcinoma.
As previously demonstrated, the "vascular normalization" process is
characterised by attenuation of abnormal tumor vessel features.
Indeed, increased pericyte coverage and a more restrained vascular
network are markers of restored tumor vessel function21–23. To
further confirm the increase in tumor vessel normalization
induced by Ro 48-8071, we analysed the effect of OSC inhibition
on tumor vessel perfusion. Immunostaining of tumor sections
from RIP-Tag2 mice revealed that Ro 48-8071 treatment greatly
improved vessel function, as revealed by labelling perfused blood
vessels with FITC-conjugated lectin injected into the circulation of
tumor-bearing mice (Figure 3A and B). Moreover, perfused vessel
density analysis revealed an increase by 50% of lectin-positive vessels
on total vessel number in Ro 48-8071 treated RIP-Tag2 compared
with controls (Figure 3C). Based on the observed increase in tumor
vessel normalization induced by Ro 48-8071, we investigated
whether this drug was able to enhance the anti-cancer effects of
chemotherapy. It was interesting to observe that HCT116
xenografted mice treated with a combination of 5-fluorouracil (5-
FU) (30 mg/kg, every 5 days) and Ro 48-8071 presented a greater
effect in terms of impaired tumor progression. Indeed, 5-FU
monotherapy resulted in a 25% reduction in tumor burden,
compared with the vehicle-treatment group, whereas the addition
of Ro 48-8071 to this regimen resulted in 71% cancer growth inhi-
bition, compared to the control group (Figure 3D). The combination
of 5-FU with Ro 48-8071 reduced the incidence (83%) and the
number (89%) of lung metastasis more dramatically, compared to
vehicle-treated animals, and compared to 5-FU administered as
a single drug, which was less efficient in halting metastasis
dissemination (incidence dropped by 33%, and the number of lung
metastases by 44% versus controls) (Figures 3E and F). We next
assessed whether results obtained in vivo with combination
therapy could be attributed to a direct effect on tumour cell
growth. To this end, we studied the effect of 5-FU, Ro 48-8071 and
5-FU 1 Ro 48-8071 on cell growth inhibition in cell lines of
colorectal cancer (HCT116). As expected, 5-FU displayed a
decrease in tumor cell proliferation, as assessed by cell viability
assay, compared with untreated cells. On the other hand, Ro
48-8071 did not significantly induce growth inhibition at con-
centrations up to 10 mM. Notably, 5-FU 1 Ro 48-8071 co-
administration in HCT116 cells led to a slightly higher
cytotoxic effect, compared to 5-FU alone only at the top
concentration of 50 mM 5-FU (Figure 3G). However, this
exceeds the range of plasma concentrations measured in
colorectal cancer patients receiving infusion 5-FU24. Therefore,
we believe that the anti-tumoral effect of Ro 48-8071 in vivo
could be mainly attributed to tumor blood vessel normalization,
which enhances the delivery efficiency of chemotherapeutic drugs
within the neoplastic mass.
Ro 48-8071 suppresses tumor proliferation and increases apop-
tosis both in vessels and cancer cells in RIP-Tag2 mice and in
HCT116 and HPAF-II models. OSC inhibition by Ro 48-8071
reduced proliferation levels by 51% in RIP-Tag2 mice and by 58%
and 52% in HCT116 and HPAF-II xenografts, respectively
(Figures 4A–C; Supplementary Figures S4A–S4C). Concomitantly,
Ro 48-8071 exerted a strong pro-apoptotic effect on the different
models (Figures 4D–H). Remarkably Ro 48-8071 induced tumor
vessel apoptosis in both RIP-Tag2 and HCT116 and HPAF-II mice
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9054 | DOI: 10.1038/srep09054 3
 M
ec
a3
2 
α
SM
A 
F
E
A
0
10
20
30
40
50
60
70
80
90
Control
 Ro 48-8071
HCT116     HPAF-II
**
**
HCT116  HPAF-II 
M
ec
a3
2 
α
SM
A 
M
ec
a3
2 
aS
M
A 
C
on
tr
ol
 R
o 
48
-8
07
1
Ve
ss
el
 a
re
a 
(%
)
Control  Ro 48-8071
4
0
6
2
8
**
A
D
RIP-Tag2
C
0
10
20
30
40
50
60
70
80
90
 
 α
-S
M
A/
M
ec
a3
2 
M
FI
 (%
) *
Control  Ro 48-8071
RIP-Tag2
Control
 Ro 48-8071
Ve
ss
el
 a
re
a 
(%
)
B
HCT116     HPAF-II
** **4
0
6
2
8
10
 
 α
-S
M
A
/M
ec
a3
2 
M
FI
 (%
) 
G
RIP-Tag2 
M
ec
a3
2
α
SM
A
M
ec
a3
2
α
SM
A
Control Ro 48-8071 Control Ro 48-8071
Figure 2 | OSC inhibition reduces vessel area and increases pericyte coverage in RIP-Tag2 mice and in HCT116 and HPAF-II models. (A, B) The
percentage of surface area occupied by vessels was quantified as Meca32 positive staining. Bars show vessel density reduction in RIP-Tag2 (A), and
HCT116 and HPAF-II tumors (B) treated with Ro 48-8071, compared with controls, by 49%, 67% and 56%, respectively (**P , 0.01). (C) Pericyte
coverage was quantified bymeans of co-localisation betweenMeca-32 and a SMA. This analysis revealed an increase in pericyte coverage of 44% in Ro 48-
8071 treated RIP-Tag2, compared with untreated mice (**p, 0.01). (D) Fluorescence confocal microscopy highlighted an increase in pericyte coverage
(green) of tumor blood vessels (red) after 4weeks of Ro 48-8071 treatment of RIP-Tag2mice, comparedwith controls (arrows). (E) The graph bar shows a
33% increase in pericyte coverage in HCT116, and a 31% increase in HPAF-II, compared with controls (**p, 0.01). (F, G) Representative images of co-
localisation between the endothelial markerMeca32 (red) and the pericytemarker a SMA (green) in bothHCT116 (E) andHPAF-II (F) tumors. Scale bar
50 mm.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9054 | DOI: 10.1038/srep09054 4
0200
Control 
Ro 48-8071 
5-FU 
Ro 48-8071 + 5 -FU 
Tu
m
or
 v
ol
um
e 
H
C
T1
16
 (m
m
3 )
400
600
800
1000
1200
1400
0 3 6 9 12 15
Days of treatment
D
0
10
20
40
60
80
100
Ro 48-8071
In
ci
de
nc
e 
of
 lu
ng
 
m
et
as
ta
si
s 
(%
)
Control
Ro 48-8071+ 5-FU
5-FU
E
*
0
1
2
3
4
5
6
Nu
m
be
r o
f l
un
g 
m
et
as
ta
si
s 
7
8
9
10
F
**
Ro 48-8071
Control
Ro 48-8071+ 5-FU
5-FU
*
G
Ro
5FU
Ro+5FU
A
   
 M
ec
a 
32
  L
ec
tin
 
C
on
tr
ol
R
o 
 4
8-
80
71
RIP-Tag2 
0 0.5 1 2 10
Ro 48-8071 concentration μM
0 5 10 25 50
5FU concentration   μM 
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tr
ol
)  
0%
20%
40%
60%
80%
100%
120%
*
C
ol
oc
al
iz
at
io
n 
ar
ea
 (m
m
2 )
Control  Ro 48-8071
400
0
600
200
800
1000
**
B
**
*
*
Le
ct
in
+  v
es
se
ls
 / 
ve
ss
el
 d
en
si
ty
 (m
m
2 )
40
0
60
20
80
**
Control    Ro 48-8071
C
Figure 3 | Ro 48-8071 improves tissue perfusion and enhances 5-Fluorouracil anti-tumoral effect in human colon carcinoma by reducing tumour
volume andmetastasis formation. (A) Ro 48-8071 increases the amount of FITC-lectin perfused vessels (arrows), compared with untreated insulinomas.
Results are from 5 fields permouse (n5 10 per treatment group). (B) Colocalization analysis between lectin perfused vessels (green) andMeca32 (red) in
RIP-Tag2 mice. Quantification is shown as mean 6 SEM of colocalization area (in mm2) *P , 0.05, Student t- test. (C) The graph shows in black the
fraction of lectin-positive vessels normalized on total vessels (perfused vessel density) and in white the percentage of not-perfused vessels on the total
vessel number. Ro 48-8071 increased by 50% the lectin-positive vessels on the total vessel number, compared with controls. (** P, 0.01, Student t- test.).
(D) HCT116mice were treated with: (1) 5-FU 30 mg/kg, (2) Ro 48-8071, (3) 5-FU 1Ro 48-8071 or (4) vehicle for 2 weeks after tumour volume reached
an average of 150-200 mm3 (n 5 10/group). Mean 6SEM tumor volumes are reported for each treatment. (*P , 0.05 and *P , 0.01; ANOVA test.)
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5-FU resulted in 71% cancer growth inhibition, compared with the vehicle-treatment group. (E,F) Combined Ro 48-8071 and 5-FU diminished both the
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(Figures 4D–F). Of note, in vitro assays clearly showed that Ro 48-
8071 was unable to directly inhibit cell proliferation in both tumour
cell lines, unless a very high concentration of 30 mM was applied
(Supplementary Figures S5A and S5B), which may reflect the lack
of specificity and off-target effects of Ro 48-8071 at supraphysiolo-
gical doses. Together these findings suggest that the anti-tumoral
effect obtained by OSC inhibition is mainly mediated by the strong
anti-angiogenic effect of Ro 48-8071, although we cannot rule out a
direct cytotoxic effect on cancer cells when the compound is used at
high doses exceeding 10 mM.
Inhibition of OSC in vitro impairs EC migration and adhesion,
and blocks vessel network formation inMatrigel and CAM assays.
Based on the strong observed effect of Ro 48-8071 on tumor
angiogenesis, we sought to investigate the specific influence of this
compound on endothelial cells. As known, the angiogenic process
involves complex mechanisms, such as migration and adhesion of
vascular cells to different extracellular matrix proteins25. Therefore,
we first evaluated the ability of Ro 48-8071 to inhibit ECmigration in
a chemotaxis assay.We found that 1 mMof Ro 48-8071 was themost
efficient concentration capable of inhibiting EC migration (data not
shown). In fact, at this dosage, Ro 48-8071 significantly impaired
both VEGF-induced and baseline EC migration by 52% and 57%,
respectively, compared with the control group (Figure 5A).
Moreover, Ro 48-8071 significantly inhibited the adhesion of ECs
to different extracellular matrices, such as vitronectin (61%),
fibronectin (58%) and collagen I (52%) (Figures 5B–D). Of note,
1 mM of Ro 48-8071 did not affect EC proliferation (Sup-
plementary Figure S5C). In order to further confirm that Ro 48-
8071 specifically interferes with EC motility, we performed a cell
migration and invasion assays by employing both HCT116 and
HPAF-II tumour cell lines. Notably, Ro 48-8071 did not inhibit
cancer cells invasion in trans-well chamber inserts coated with
Matrigel (Supplementary Figure S6). These results strengthen and
corroborate our findings indicating that the inhibitory effect of Ro
48-8071 mainly acts by impairing EC motility and does not affect
the proinvasive and prometastatic activity of both HCT116 and
HPAF-II cells.
We used a Matrigel assay to evaluate whether OSC inhibition
could impair vessel network formation. To this end, ECs were prev-
iously treated with 1 mMof Ro 48-8071 and re-suspended in starving
medium supplemented with VEGF-A and seeded on Matrigel-
coated plates. ECs treated with VEGF-A formed a proper vessel
network, whereas Ro 48-8071 pretreatment significantly suppressed
(70%) tube formation, compared with untreated controls.
(Figures 5E–G)
Further, we checked the effects of the inhibitor in impairing in vivo
angiogenesis by performing a CAM assay. Paper disks loaded with
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(by 73%) and in both HCT116 and HPAF-II xenografts models (by 79% and 68%, respectively), as compared to vehicle-treated controls (**p, 0.01).
Scale bar 50 mm.
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Figure 5 | Ro 48-8071 impairs EC migration, adhesion and blocks vessel formation in Matrigel and CAM assays. (A) Chemotaxis assay, using ECs
treated with Ro 48-8071 (1 mM), revealed a significant decrease in both baseline and VEGF-induced EC migration (* p, 0.05; ** p, 0.01). Values are
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FGF-2 and Ro 48-8071 were added to the CAM at day 10 of develop-
ment when vessel network is formed with a regular capillary plexus.
Similarly to what we observed with the Matrigel assay, OSC inhibi-
tion impaired the angiogenic effect triggered by FGF-2 by 84%.
(Figures 5H–J).
Itraconazole, has been found to efficiently inhibit chemotactic
migration and HUVEC tube formation26. Indeed, comparing the
anti-angiogenic effect of the two inhibitors, Ro 48-8071 was the most
effective in inhibiting vessel network formation on Matrigel and
CAM experimental models (Supplementary Figures S7A and S7B).
OSC inhibition impairs PI3K/Akt pathway activation in both ECs
and tumor cells. Based on the observed in vivo and in vitro anti-
angiogenic effect of Ro 48-8071, we sought to investigate the
molecular mechanisms by which it can affect EC motility and
vessel formation. First, we evaluated the effect on Rho GTPases,
since these proteins have previously been shown to be involved in
cytoskeleton regulation and to control both physiological and
pathological angiogenesis27,28. We did not detect any significant
reduction in RhoA activity in ECs treated with Ro 48-8071
(Supplementary Figure S8). Next, we assessed whether Ro 48-8071
was able to impair PI3K/Akt and ERK signal pathways on ECs, a
pivotal node in signalling events leading to angiogenesis29,30. Indeed,
while OSC inhibition did not affect ERK phosphorylation, EC
treatment with Ro 48-8071 for 18 and 24 hours strongly impaired
Akt phosphorylation by 53% and 62%, respectively (Figures 6A and B).
To further confirm the inhibitory effect of Ro 48-8071 on mTOR/
Akt pathway, we checked the activation level of ribosomal P70S6
kinase, which is located downstream of Akt and is phosphorylated
in response to stimuli that activate the PI3K/Akt pathway. As
observed for Akt, we found that P70S6K phosphorylation was sig-
nificantly impaired (Figures 6A and B).
Based on these observations, we analysed whether Ro 48-8071
administration decreased Akt phosphorylation in tumors of the dif-
ferent treatment groups. As assessed by phospho-Akt immunostain-
ing, we detected a dramatic decrease by 70%, 78% and 62%,
respectively, in p-Akt levels in RIP-Tag2 and colon and pancre-
atic tumor xenografts, compared with vehicle-treated animals
(Figures 6C–F). We observed a reduction in Akt activation in
both cancer cells and tumor blood vessels in all cancer models
(Figures 6C–E). Hence, we investigated whether in vitro inhibition
of OSC could impair Akt activation also in HCT116 and HPAF-II
cells. We found that Ro 48-8071 significantly inhibited Akt phos-
phorylation after 9 hours both in HCT116 and HPAF-II cells
(Figures 6G and H). In addition, Ro 48-8071 inhibited ERK phos-
phorylation both in HCT116 and HPAF-II. These data indicate that
Akt pathway inhibition could be one of themajor signallingmechan-
isms by which Ro 48-8071 could exert its powerful anti-tumoral and
anti-angiogenic effects.
Discussion
Recent studies have reported that inhibitors of the post-squalenic
steps of cholesterol synthesis, such as itraconazole, impaired angio-
genesis and tumour growth9–11,26,31,32. However, their effect on vessel
normalization and onmetastasis has not been proven as yet. Notably,
OSC, a key enzyme in the post-squalenic steps of sterol biosynthesis,
could also be considered a potential therapeutic target for the control
of cell proliferation and differentiation. For instance, OSC was sig-
nificantly up-regulated in self-renewing cells (i.e. erythroid cells)33.
Moreover, OSC inhibition was shown to significantly hamper the
viability of different cancer cell lines at micromolar concentrations,
comparable to those at which statins display an anti-tumoral
effect34,35. It has been recently proven that specific OSC impairment
can reduce the growth of oestrogen-dependent breast cancer36. Based
on these data, the selective OSC inhibitor Ro 48-8071 is a potential
and new anti-cancer drug. Our study demonstrates for the first time
that Ro 48-8071 efficiently impaired experimental angiogenesis in
several in vitro and ex-vivo assays, with stronger efficacy than the
anti-angiogenic activity described for the other post-squalenic drug,
itraconazole. Notably the inhibition of OSC strongly impaired an-
giogenesis, induced tumour vessel normalization, reduced tumor
hypoxia and hampered tumor progression in a transgenic mouse
model of neuroendocrine pancreatic tumor RIP-Tag2, and in two
mousemodels of human colon and pancreatic cancer. Differently from
itraconazole and other postsqualenic drugs exerting anti-angiogenic
effects, Ro 48-8071 strongly blocked metastatic dissemination to distal
organs in both HCT116 and HPAF-II mouse models. In addition, we
demonstrated that, differently from the other inhibitors of cholesterol
biosynthesis, the treatment with Ro 48-8071, normalizing the vascu-
lature, improved tumor vessel perfusion.
It is well known that tumor vessel normalization, a process
that occurs in response to certain anti-angiogenic therapies, which
enhance tumor vasculature efficiency in delivering oxygen and
drugs, is a remarkably advantageous anti-cancer strategy, as it
can also favour chemotherapy delivery and response to radio-
therapy21,22,37. Interestingly, we noticed enhanced anti-tumoral and
anti-metastatic effects when we combined Ro 48-8071 with the che-
motherapeutic drug 5-FU in the HCT116 colon cancer model,
compared to single treatments. Remarkably, the combination of Ro
48-8071 with 5-FU did not exert a direct effect on tumor cells, since
neither additive nor synergistic effects on the proliferation rate of
HCT116 cells were observed in vitro (andHPAF-II, data not shown),
suggesting a specific effect of this drug on the tumor microenviron-
ment. It is well demonstrated that increased tumor hypoxia promotes
the activation of several hypoxia-driven phenomena, including the
induction of cancer invasion and metastasis dissemination38,39.
As described by Jain and colleagues and by other laboratories, the
ameliorated blood vessel function induced by the treatment with
pro-normalizing agents is able to improve cancer tissue oxygenation,
promoting a less aggressive and metastatic tumor phenotype40,41.
Of note, the observed decrease of cancer hypoxia in tumors treated
with Ro 48-8071, suggests that the increase of tumor tissue oxygena-
tion induced by vessel normalization, can be part of the anti-
metastatic effect exerted by this inhibitor.
Based on the demonstrated correlation between the increase of
cholesterol and triglycerides and cancer6, the use of this cholesterol-
lowering agent against different tumor types in clinical practice may
have a further advantage. A correlation has been described between
hyperlipidaemia/hypercholesterolemia and progression of colon and
pancreatic cancers42,43. Several clinical studies have employed statins
to treat pancreatic cancer, considering their capacity to decrease
blood cholesterol levels and reduce tumor cell proliferation.
However, data on the anti-tumorigenic properties of statins in pan-
creatic cancer are still questionable, and information is scarce about
the effect of statins in specific high-risk subgroups44. Hence, our data
suggest that the treatment of these two tumor types with Ro 48-8071,
in parallel to its anti-angiogenic effect, could help to reduce the
elevated levels of circulating cholesterol and triglycerides in cancer
patients, thus alleviating dyslipidaemia-induced tumor growth and
metastasis.
It has been established that elevated cholesterol levels can lead to
PI3K/Akt phosphorylation, and that cholesterol depletion on the
membrane surface can inhibit PI3K/Akt and ERK pathways in sev-
eral tumors45. mTOR/Akt inhibition, along with ERK 1/2 impair-
ment, has been observed in ECs treated with itraconazole26,32.
Similarly, Ro 48-8071 specifically inhibited Akt phosphorylation in
vitro and in vivo both in tumor vessels and cancer cells across all
models. The mTOR/Akt pathway is known to play a critical role in
the regulation of several processes that control cell growth and pro-
liferation46, as well as tumor progression and angiogenesis30,47. Our
data suggest that part of the mechanisms by which Ro 48-8071 im-
pairs angiogenesis and, importantly, normalizes tumour vasculature
www.nature.com/scientificreports
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Figure 6 | OSC inhibition blocks in vitro and in vivo PI3K/Akt pathway activation in endothelial and cancer cells. (A, B) Akt, ERK and P70S6K protein
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representative of 5 independent experiments. (C,E) Tumors from RIP-Tag2 (C) and HCT116 (D) and HPAF-II (E) xenografts treated with Ro 48-8071
and vehicle were subjected to confocal analysis, and Akt activation and localisation were assessed by co-staining of anti p-Akt withMeca32. Activated Akt
was highly expressed in both vessels (arrows) and tumor cells in baseline conditions, and it was strongly inhibited after Ro 48-8071 treatment. The image
presents confocal microscopy of 5 fields per mouse. (F) Akt activation level was quantified by fluorescence intensity mean (MFI) (**P, 0.01 with the
Student T-test). (G, H) Western blot analysis on HCT116 and HPAF-II cancer cells showed an inhibition of Akt/P70S6K pathway and of ERK
phosphorylation after 9 hours of incubation with Ro 48-8071(1 mM). Relative protein levels were normalised to b-tubulin. Values are mean 6SD,
(*p , 0.05 for Akt, #p , 0.05 for pP70S6 kinase, 1p , 0.05 for ERK; ANOVA test).
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in pancreatic and colon cancers may be due to the impairment
of Akt phosphorylation, suggesting that the specific inhibition of
PI3K/Akt may represent a new strategy to normalize the tumor
vasculature.
Although Ro 48-8071 reduced tumor growth and metastasis
formation mainly by acting on tumor vasculature, we observed an
inhibition of Akt phosphorylation also in tumor cell lines, suggesting
that, at least in part, Ro 48-8071 can exert a direct effect on tumor
cells.
Othermechanisms could be suggested to explain the specific effect
on tumor progression, angiogenesis and vessel normalization exerted
by Ro 48-8071, compared to other inhibitors of the post-squalenic
step of cholesterol biosynthesis. It is known that cholesterol and its
derivatives can regulate Hedgehog (Hh) synthesis and modulate Hh
signalling48. Recent studies have demonstrated that itraconazole
inhibited the Hh pathway in ECs26 and in tumour cells12. Notably,
it has been shown that Sonic Hedgehog (Shh) induced capillary
morphogenesis in ECs and activated bone marrow-derived EC pro-
genitors by activating the PI3-kinase/Akt signalling pathway49,50. On
the other hand, the Hh pathway is highly activated in many tumor
types, including pancreatic and colon cancers51,52. Interestingly, it has
been shown that oxysterols (OHCs), oxygenated derivatives of cho-
lesterol, can enhance the activity of Smoothened (SMO), a member
of Hh pathway, and contribute to tumour progression48. We can
estimate that OSC inhibition by Ro 48-8071 in tumor vasculature
and cancer cells may reduce OHC levels and, consequently, inhibit
Hh and PI3-kinase/Akt pathways, thus impairing tumour angiogen-
esis and metastasis formation. Further studies are needed to better
assess the mechanisms by which Ro 48-8071 directly impairs Akt
signalling pathways or modulates other related pathways in cancers.
In conclusion, we unveiled the post-squalenic enzyme OSC as a
crucial target to inhibit tumor angiogenesis, halt metastatic dissem-
ination, normalize the vasculature and, consequently, enhance the
efficacy of chemotherapeutic drugs, assigning to Ro 48-8071, its
specific inhibitor, the role of potential novel anti-angiogenic and
anti-metastatic drug.
Methods
Chemistry. Ro 48-8071 (Sigma-Aldrich) was dissolved in ethanol according to the
manufacturer’s instructions.
Cell culture. Human umbilical vein ECs (HUVECs) were isolated from umbilical
cord veins and grown as previously described53. Pancreatic ductal adenocarcinoma
HPAF-II (CRL-1997) and colon carcinoma HCT116 (CCL-247) were purchased
from American Type Culture Collection (ATCC, VA, USA) and grown according to
the manufacture’s instruction. Cells were routinely screened for the absence of
mycoplasma contamination with the Venora¨GeMMycoplasma Detection Kit (Sigma
Aldrich).
Mouse tumor models. The RIP-Tag2 transgenic mouse model has been previously
described19. Xenograft mice were generated by subcutaneously injecting either
HPAF-II cells (5 3 105 cells/mouse) into the right posterior flanks of 7-wk-old
immunodeficient NOD/SCID male mice54, or HCT116 cells (2 3 105 cells/mouse)
into 7-wk-old immunodeficient NOD/SCID gamma (NSG) male mice (Charles
River, MA, USA)55. Tumor growth was monitored twice a week. When tumors
reached a volume of approximately 150–200 mm3, mice were randomised into the
different treatment groups.
All animal procedures were approved by the Ethics Committee of the University of
Turin, and by the Italian Ministry of Health, in compliance with international laws
and policies.
Therapeutic treatments. Tumor-bearing RIP-Tag2 mice (10/group) were treated for
4 weeks (from 12 to 16 weeks of age) by daily gavage of 10 mg/kg of Ro 48-8071 or
vehicle (1% methylcellulose) as control group. Mice were regularly monitored for
changes in weight and health status. Conversely, HCT116 or HPAF-II mice (10/
group) were daily treated for two weeks. 5-fluorouracil alone or in combination with
Ro 48-8071 was administered by intraperitoneal injection (30 mg/kg, every 5 days) to
HCT116 xenograft mice. Total tumor burden was quantified by measuring with a
caliper and estimating the volume of individually excised macroscopic tumours
(.1 mm3) with the formula: V 5 a 3 b2 3 0.52, where a and b represent the longer
and shorter diameter of the tumor, respectively.
Metastasis analysis. In HCT116 xenografts the formation of superficial pulmonary
metastasis in the lungs was analysed after two weeks of treatment by contrasting them
with black India ink infusion, and counted on dissected lung lobes under a
stereomicroscope56. The presence of liver metastasis in HPAF-II mice was assessed by
analysing serial H&E-stained sections of paraffin-embedded tissues, as previously
described23.
Tissue preparation and immunohistochemistry analysis. Tissue preparation and
histology analysis were carried out as previously described23. Immunohistochemistry
and immunofluorescence analyses were performed as previously detailed23 with the
following primary antibodies: purified Rat monoclonal anti-Panendothelial Cell
antigen (550563, clone Meca32, BD Pharmingen, USA), diluted 15100; Rabbit
polyclonal anti-SMA (AB5694, Abcam, UK), diluted 15100; Rabbit monoclonal anti-
cleaved caspase 3 (asp175, clone 5A1, Cell Signaling, USA), diluted 15100; Rabbit
monoclonal anti-pAkt (S473, 4060 L, Cell Signaling) diluted 1550; Rabbit polyclonal
anti-Ki67 (AB15580, Abcam), diluted 15100.
Confocal microscopy quantifications. The surface area occupied by vessels was
quantified through the Image-ProPlus 6.2 software (Media Cybernetics) as the area
occupied by Meca32-positive structures, compared with the total tissue area
visualised by DAPI. To quantify pericyte coverage (a-SMA, green channel) in each
image, we drew a region of interest (ROI) close to each blood vessel (Meca32, red
channel), and then quantified themean fluorescence intensity (MFI) of red and green
channels using the Leica Confocal Software Histogram Quantification Tool. In order
to normalize the vessel number values obtained, we calculated the ratio between red
and green channel MFI; values are expressed as percentage of red-green co-staining.
To determine the expression levels of caspase 3 (green channel), and phospho-AKT
(green channel) in each analysed image, we considered 5 random ROIs of the same
size. Then we measured the MFI of the green channel, and we normalized the values
by comparing caspase 3- or p-AKT- stained area with the total cells present in the
tissue area23.
Tumour vessel perfusion.To evaluate tumor vessel perfusion, 0.05mg FITC-labelled
tomato lectin (Vector laboratories, CA,USA)were injected i.v. into RIP-Tag2mice, as
previously described23. After 10 minutes, the animals were euthanised, and lectin
distribution in co-staining with the endothelial marker Meca32 was visualised by
fluorescent confocal microscopy. Tumor perfusion was quantified as colocalization
signal between fluorescent lectin (red channel) and tumor blood vessels (green
chennel) by means of ImageJ software maintaining the same area and fluorescent
setting. At least 5 images at a magnification of 403 were analyzed for each sample,
considering 8 mice per treatment group.
Cell Viability Assay. 2 3 103 colon cancer cells (HCT116) were suspended in
complete medium (RPMI-1640, 10% FCS) and seeded into 96-well plates. The
next day drugs were added to triplicate wells at increasing concentrations
corresponding to: 0.5 - 1 - 2 and 10 mM of Ro48-8071, 5 - 10 - 25 - 50 mM 5-FU
or a combination of both at each dose. A control with no drug and consisting of
media only was included in each plate. Incubation was stopped after 72 hours and
cell viability following incubation was evaluated by CellTiter-GloH Luminescent
Cell Viability Assay (Promega, WI, USA) according to the manufacturer’s
recommendations using the VICTOR X Multilabel Plate Readers (Perkin Elmer,
MA, USA). Values were normalized on controls and on the maximum doses of 5-
FU, which killed all cells present. The percentage of cell viability/controls was
evaluated. The quantification of the synergistic effect in these drug combination
and dose-response studies was assessed by means of the Chou-Talalay method57,
while an ANOVA test was used to determine the significance between the
different experimental conditions.
Migration assay. ECs (10,000 cells/well), pre-treated overnight with 1 mM of Ro 48-
8071, were seeded on the upper surface of a polycarbonate 8-mm porous Transwell
membrane (BD Falcon, USA) in the presence or absence of 10 ng/mL VEGF-A or
1 mM Ro 48-8071, while M199 serum free medium 6 VEGF-A was added into the
multiwell plate. Cells were allowed tomigrate through the membrane for 4 h, fixed in
2.5% glutaraldehyde and stained with 0.1% crystal violet58.
Cell adhesion assay. HUVECs were incubated with 1 mM of Ro 48-8071 overnight.
The next day, 104 ECs suspended in serum-free medium and supplemented with
1 mMRo 48-8071 were added to the 96-well microtitre plate coated with 1 mg/mL or
1.5 mg/mL of rat collagen, human fibronectin and human vitronectin (Sigma
Aldrich). After 30 minutes, cells were fixed and stained as previously described51.
Matrigel assay. 8 mg/mLMatrigel (BD Biosciences, USA) was added to each well of a
24-well plate and incubated at 37uC for 20 minutes to allow gel formation. Then 2 3
104 cells suspended in serum free medium, VEGF-A (10 ng/mL) and 1 mMof Ro 48-
8071 were plated. 12 hours after, capillary-like structures were photographed by the
use of Image ProPlus program and quantified by winRHIZO Pro software (Regent
Instruments Inc)59. Values were expressed as cell morphogenesis index obtained by
normalizing the length of the tubular network to controls.
Chick Chorioallantoic Membrane (CAM) assay. Fertilised chicken eggs were
incubated at 37uC in a humidified incubator, as previously described60. On day 10 of
incubation, CAM were added with sterilised paper disks treated with hydrocortisone
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(3 mg/mL). The disks were loaded with fibroblast growth factor (FGF-2, 100 ng/mL)
in the presence or not of 1 mM Ro 48-8071. After 48 h of incubation, CAM vessels
were isolated, fixed and photographed in ovo with a stereomicroscope using the
Image ProPlus analysis software. Angiogenesis was measured as number of vessel
branch points contained in a circular region described by the filter disk.
Western Blot analysis. Western Blot experiments were performed as previously
described23. Briefly, the following primary antibodies were used: rabbit anti-phosho-
Akt (Ser473, D9E, Cell Signaling), mouse anti-phospho-p44/42 MAPK (ERK1/2)
(Thr202/Tyr204, E10, Cell Signaling), rabbit anti-Phospho-p70 S6 Kinase (Thr389,
Cell Signaling) and rabbit anti-b-tubulin (Santa Cruz Biotechnology, USA)
antibodies.
Statistical analysis. The results of all experiments are expressed as mean 6SD.
Statistical analyses were performed using, t-test or ANOVA test to compare more
than two experimental conditions. A p value below 0.05 was considered significant.
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